MedPath

This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence

Not Applicable
Completed
Conditions
Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
Interventions
Device: Coaptite®
Registration Number
NCT00996489
Lead Sponsor
Merz North America, Inc.
Brief Summary

This is a post approval study of Coaptite® in the treatment of female urinary incontinence.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
459
Inclusion Criteria
  • Has female stress urinary incontinence that is due to intrinsic sphincter deficiency
  • Has a baseline pad weight of greater than or equal to 50 grams
  • Has viable mucosal lining at likely site of injection (bladder neck)
  • Is at least 18 years of age
  • Understands and accepts the obligation and is logistically able to present for all scheduled study visits
  • Signs written informed consent
Exclusion Criteria
  • Has had a previous treatment for urinary incontinence with a urethral bulking agent other than Coaptite® or collagen
  • Has detrusor instability
  • Has bladder neuropathy
  • Has nocturnal enuresis (bed wetting)
  • Has Grade II or III prolapsed bladder
  • Has overflow or functional incontinence
  • Has significant history of urinary tract infections without resolution
  • Has current or acute conditions of cystitis or urethritis
  • Has history of significant pelvic irradiation
  • Is pregnant or lactating

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CoaptiteCoaptite®-
Primary Outcome Measures
NameTimeMethod
Number of Participants With Change From Baseline in Stamey Grade Scores Over TimeBaseline up to Months 6 and 12

The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

Number of Participants Who Had at Least One Point Improvement in Stamey Grade Scores Compared to BaselineMonths 6, 12, 18, 24, 30, and 36

The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)Baseline up to Month 36
Incontinence Status as Assessed by Stamey Grade ScoreBaseline and Months 6, 12, 18, 24, 30, and 36

The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

Number of Participants With One Point Improvement in Stamey Grade Scores up to Month 12Baseline up to Month 12

The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

Secondary Outcome Measures
NameTimeMethod
Volume of Coaptite Injected Per TreatmentBaseline, Baseline to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36
Number of Participants Who Received Each of the Six Coaptite InjectionsBaseline up to Month 36

Coaptite injection were given to any participant during the 36 months of evaluation.

Number of Participants With Alternative Treatments for IncontinenceBaseline up to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36

Number of participants with alternative treatment such as kegel exercises, sling, sling/cystocele repair, surgery, permanent abdominal tube, intravesical botox, sling/graft, sling removal, estradiol vaginal cream, bladder neck suspension, tension free vaginal tape, biofeedback, polydimethylsiloxane injections, solifenacin orally, bladder specific control physical therapy, for stress urinary incontinence were assessed.

Time to Coaptite RetreatmentBaseline up to Month 36

Time to additional coaptite treatment or any other alternative treatment for stress urinary incontinence was recorded to assess the durability of effect.

Incontinence Quality of Life (iQoL) ScoresBaseline and Months 6, 12, 18, 24, 30, and 36

The iQoL measured the effect of urinary incontinence on QoL. It was divided into 3 subscales: 1 (avoidance and limiting behaviour); 2 (psychosocial impact), and 3 (social embarrassment). The iQOL was comprised of 22 items, each with the response scale from 1 (extremely) to 5 (not at all). A mean score for each subscale was calculated (averaging the scores for the items in each subscale) as well as a total score for all 22 items (sum of all subscale scores). The scores were then transformed to a scale score ranging from 0 to 100 points, where higher scores indicated less impact of incontinence on QoL.

Number of Participants With Urge Incontinence Medication (UIM) StatusBaseline up to Month 36

The use of urge incontinence medications was collected pre-treatment and post-treatment.

Mean Number of Sites Injected by CoaptiteBaseline, Baseline to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36
© Copyright 2025. All Rights Reserved by MedPath